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infections
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Abstract
Introduction: Infections can impact the reproductive health of women and hence may influence pregnancy
related outcomes for both the mother and the child. These infections range from sexually transmitted infections
(STIs) to TORCHS infections to periodontal disease to systemic infections and may be transmitted to the fetus
during pregnancy, labor, delivery or breastfeeding.
Methods: A systematic review and meta-analysis of the evidence was conducted to ascertain the possible impact
of preconception care for adolescents, women and couples of reproductive age on MNCH outcomes. A
comprehensive strategy was used to search electronic reference libraries, and both observational and clinical
controlled trials were included. Cross-referencing and a separate search strategy for each preconception risk and
intervention ensured wider study capture.
Results: Preconception behavioral interventions significantly declines re-infection or new STI rates by 35% (95% CI:
20-47%). Further, condom use has been shown to be the most effective way to prevent HIV infection (85%
protection in prospective studies) through sexual intercourse. Intervention trials showed that preconception
vaccination against tetanus averted a significant number of neonatal deaths (including those specifically due to
tetanus) when compared to placebo in women receiving more than 1 dose of the vaccine (OR 0.28; 95% CI:
0.15-0.52); (OR 0.02; 95% CI: 0.00-0.28) respectively.
Conclusion: Preconception counseling should be offered to women of reproductive age as soon as they test HIV-
positive, and conversely women of reproductive age should be screened with their partners before pregnancy. Risk
assessment, screening, and treatment for specific infections should be a component of preconception care
because there is convincing evidence that treatment of these infections before pregnancy prevents neonatal
infections.
Introduction
Infections can impact the reproductive health of women
and hence may influence pregnancy related outcomes
for both the mother and the child. These infections
range from sexually transmitted infections (STIs) to
TORCH infections to periodontal disease and may be
transmitted to the fetus during pregnancy, labor, deliv-
ery or breastfeeding.
STIs are a serious universal reproductive health concern
with the weight of the disease falling excessively on
women, especially those who are young or socioeconomi-
cally disadvantaged. The World Health Organization esti-
mates of syphilis infection among pregnant women stands
at 2 million [1]. Congenital syphilis can have devastating
complications including stillbirth, premature birth, neona-
tal death, developmental delay, blindness, deafness and sei-
zures. Similarly, gonorrhea during pregnancy is associated
with chorioamnionitis, premature rupture of membranes,
preterm labor and can potentially cause severe conjuncti-
vitis in the newborn. Chlamydia too in the pregnant
woman can have serious consequences for her neonate,
including conjunctivitis and pneumonia. With timely
detection and treatments prior to conception, thereby
helping the mother-to-be to achieve an optimal state of
health earlier, these maternal and fetal complications can
be averted.
Initially, HIV/AIDS largely infected high-risk popula-
tions, such as commercial sex workers and injecting drug
users. Currently, however, the demographic with the* Correspondence: zulfiqar.bhutta@aku.eduDivision of Women and Child Health, Aga Khan University Karachi, Pakistan
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highest incidence rate is women of reproductive age [2].
Women are at particular risk of being infected in stable
heterosexual relationships, since they often lack the skills
to negotiate safe sexual behaviors. Approximately 15.9
million women who are HIV positive today could poten-
tially transmit the virus to their future children [3,4].
Babies born with HIV are more likely to develop AIDS
sooner and have more serious complications. Addition-
ally, HIV-positive women are more likely to terminate
their pregnancies, give birth to low birth weight (LBW)
babies, deliver preterm, or experience stillbirths [5-8].
Perinatal HIV transmission still accounts for ≥90% of the
cases of pediatric acquired immunodeficiency syndrome
in the United States (US) [9]. Although 18-40% of
women in the US become pregnant after an HIV diagno-
sis [10,11], forty percent of these infants are born to
mothers who are unaware of their HIV status. Therefore,
in addition to timely preconception screening, these
women require close monitoring of the disease status
and treatment protocol as the state of pregnancy does
not make the disease worse and women with HIV can
have healthy pregnancies. However, women with low
CD4 counts or active infections may have more compli-
cations. Also, while highly active antiretroviral therapy is
contraindicated in the first trimester, treatment with
anti-retroviral therapy (ART) has drastically decreased
the mother to child transmission in the past few decades.
Detection and treatment of STIs is inadequate without
reducing risky behaviors (multiple partners, unprotected
intercourse). Hence the current focus of interventions
targeting STIs in women of child-bearing age, including
HIV, focus on promoting safe sex behaviors and the
provision of easily accessible contraception. This does
not only empower women but enables them to plan
their pregnancies until their infection has been eradi-
cated (controlled in the case of HIV) and/or their treat-
ment regimen has been optimized.
TORCH is another set of infections with serious neona-
tal complications, with congenital cytomegalovirus being
the leading cause of hearing loss in children. The neonatal
complications are more severe if acquired during early
pregnancy and this necessitates early screening before the
critical period of fetal organogenesis. Immunization
against those infections that are vaccine-preventable
would have greater benefit if they were also targeted to
young women of reproductive age.
The incidence of STIs remains very high in low- and
middle- income countries (LMICs) being highest in
urban men and women in their second to fourth decade
of life when sexual activity is highest [12]. Adolescents
continue to be at high risk for acquiring an STI owing
to a greater likelihood than adults of having multiple
sexual partners, engaging in unprotected intercourse,
selecting high-risk partners and older partners [13].
Other risky behaviour that increases the incidence of
STI includes substance abuse [14]. STIs during preg-
nancy are associated with adverse pregnancy outcomes
ranging from early abortion and premature births to
congenital infections and death [15,16]. Many studies
have shown between a two- and five-fold increased risk
for HIV infection among persons who have other STIs
[17], possibly increasing the occurrence of poor preg-
nancy outcomes even more.
STIs and especially HIV are a huge social stigma,
compounded by lack of knowledge of safe and effective
options and access to services or contraceptive products
to prevent unplanned pregnancies. Options-based dialo-
gues with their healthcare providers about integrated
family planning and reproductive health care help
enlighten and empower these women with regards to
their reproductive choices.
This review deals with global evidence on interven-
tions that have met with some degree of success in
addressing the issue of infections in women of child-
bearing age, especially STIs and HIV. It also includes
current evidence on the success of vaccination, espe-
cially tetanus, in reducing neonatal deaths.
Methods
This paper systematically reviewed all literature published
up to December 2012 to identify studies describing the
effectiveness of preconception (period before pregnancy
and between pregnancy) interventions for prevention and
management of infections such as HIV/AIDS, STIs, cyto-
megalovirus, and periodontal infections and their impact
on maternal, newborn and child health (MNCH) out-
comes. Electronic databases such as PubMed, Cochrane
Libraries, EMBASE, and WHO Regional Databases were
searched to identify experimental and observational stu-
dies on the topic. Papers were also identified by hand
searching references from included studies. No language
or date restrictions were applied in the search. The find-
ings were presented at international meeting [18,19] and
shared with professionals in the relevant fields of maternal
and child health, following which results were updated
based on current searches and expert opinion. Studies
were included if they reported the effectiveness of inter-
ventions for prevention and management of preconception
infections on MNCH outcomes. Methodology is described
in detail elsewhere [20].
For the studies that met the final inclusion criteria, we
abstracted data describing study identifiers and context,
study design and limitations, intervention specifics and
outcome effects into a standardized abstraction form. The
quality of experimental studies were assessed using
Cochrane criteria [21], whereas STROBE guidelines were
used to assess the quality of observational studies [22]. We
conducted meta-analyses for individual studies and pooled
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statistics was reported as the odds ratio (OR) and relative
risk (RR) between the experimental and control groups
with 95% confidence intervals (CI). Mantel–Haenszel
pooled RR and corresponding 95% CI were reported or
the Der Simonian–Laird pooled
RR and corresponding 95% CI where there was an
unexplained heterogeneity. All analyses were conducted
using the software Review Manager 5.1 [23]. Heteroge-
neity was quantified by Chi2 and I2, in situations of high
heterogeneity, causes were explored and random effect
models were used.
Results
The review identified 897 papers from search in all data-
bases. After the initial title and abstract screening, 118
full texts were reviewed to identify papers which met
the inclusion criteria and had the outcomes of our inter-
est. Seventy studies were finally selected for abstraction
and analysis (Figure 1). Information related to each




This review assessed the literature pertaining to the effects
of gynecologic infections in women in the preconception
period on maternal, newborn and child health (MNCH)
outcomes and interventions intended to reduce these
infections and hence any associated morbidity/mortality.
One essential point to keep in mind is the great overlap
between interventions targeting STIs, HIV, teenage preg-
nancies and unwanted pregnancies (The latter two are dis-
cussed in detail elsewhere [24]). As far as was possible the
data found was disaggregated to focus only on the effect of
STIs.
The review identified 10 intervention studies [25-34].
The pooled analysis of three interventions studies [25-27]
showed that post-intervention STI prevalence signifi-
cantly decreased by 22% (Figure 2). Behavioral treatments
in conjunction with STI management reduced the inci-
dence of gonorrhea by 57% [25]. Healthcare interventions
increasing access and availability of STI management led
to a significant decrease in syphilis [26]. Mass treatment
with antibiotics significantly dropped the rates of syphilis,
trichomoniasis and bacterial vaginosis [27].
For behavioral interventions, re-infection or new STI
rates significantly declined (OR 0.65 95% CI 0.53-0.80) at
1 year after the intervention [32-34]. The Magnolia Case
Management project also showed significant reductions in
the incidence and prevalence of STIs by educating women
about well-woman care and making healthcare more
accessible [28]. Schillinger et al. [29] found a non-signifi-
cant 20% decrease in the risk of re-infection, with Chlamy-
dia, among women in the patient delivered partner
treatment arm than among those in the self-referral arm.
On the other hand, Branson et al. [30] did not report any
Figure 1 Search flow diagram
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difference in the rate of new STIs among those receiving
information, motivation and skills versus those receiving
standard counseling. Similarly Boyer et al. [31] found no
difference in new STIs six-months post skills sessions ver-
sus standard risk-reduction counseling.
Most studies reviewed for interventions for STI control
reported outcomes related to safer sexual behaviors. The
analysis showed interventions promoted overall safer
practices in the subjects especially in terms of a two-fold
increase in condom use (Figure 3) [25,27,35,36]. Other
studies also showed improved condom use after motiva-
tional, skill-based interventions [30,31]. In Thailand STI
rates have been successfully reduced through enforced
condom use [37].
HIV/AIDS prevention strategies
Although half of women who are pregnant and HIV-
positive receive ART, little data exists on prevention of
Figure 2 Prevalence of STDs in mass treatment vs. placebo: evidence from controlled trials Citations to the included studies: Mayaud
1997 [26], Wawer 1999 [27], Kamali 2003 [25]
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mother-to-child transmission (PMTCT) through inter-
ventions before pregnancy [38].
Reducing the burden of HIV in women of reproductive
age will prevent transmission of the virus to the next gen-
eration and ensure that children do not lose their
mothers to AIDS. This review assessed studies of any
intervention in women age 15-45 who were not currently
pregnant, that improved MNCH outcomes or reduced
the incidence of HIV. It was previously postulated that
participants in HIV prevention efforts might perceive
their risk for transmission to be reduced. Multiple studies
have since confirmed that various interventions- includ-
ing risk reduction [39], ART [40], post-exposure prophy-
laxis [41], and voluntary counseling and testing (VCT)
[42] increase safe sexual practices, even in people who
are HIV-positive [43] which would presumably reduce
HIV transmission. Hence this review also includes HIV
preventive interventions that showed an impact on safe
sex behaviors. Since the outcome of interest was reduced
transmission, the review also included studies in which
the outcome was incidence in men of reproductive age.
The review did not, however, include studies where cou-
ples used assisted reproductive technologies (such as
intracytoplasmic sperm injection or sperm washing) to
conceive, since such procedures are expensive and not
yet accessible to the population in general, even though
they minimize the risk of transmission. Although the risk
of transmission is much higher in certain groups such as
commercial sex workers and intravenous drug users, the
review only described some studies. Thus public health
programs to prevent HIV must target men and women,
adolescents and adults, couples and individuals, as well as
focus more intensive efforts at high-risk populations and
their partners.
The review identified 55 trials [25,27,32,35,44-94]. Stu-
dies that reviewed the impact of pre-exposure prophylaxis
(PrEP) [45,46], which entails the seronegative partner
using antiretroviral drugs, especially tenofovir around the
time of conception to minimize the risk of transmission,
found an incidence rate ratio of 0.35 (95% CI: 0.03-1.93)
for HIV/AIDS, however, the trial lacked study power due
to inadequate person-years of follow-up. On the other
hand, ART for people who are HIV-positive (treatment as
prevention) has consistently been shown to lower the inci-
dence rates of HIV, not just among serodiscordant couples
[44], but even in the entire population. As a rather proxi-
mal intervention, this review found that male circumcision
significantly reduces the risk of acquiring HIV (RR 0.49;
95% CI 0.40-0.59), but is not effective in preventing trans-
mission from HIV-positive men to their partners (RR 1.10;
95% CI: 0.76-1.58) (Figure 4) [47-51].
Studies also showed that microbicides non-significantly
increases the risk of HIV infections (HR 0.89; 95% CI:
0.73-1.08) (Figure 5) [46,52-55]. Whereas, condom use
during intercourses decreases the risk by 77% (RR 0.23;
95% CI: 0.07-0.72): (Figure 6) [56-60].
Figure 3 Safer sexual behavior in Intervention vs. Control groups: evidence from controlled trials Citations to the included studies:
Grosskurth 1995 [35], Wawer 1999 [27], Kamali 2003 [25], Van Devanter 2002 [36]
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The review also pooled intervention trials that
reported whether intercourse (especially vaginal) was
protected through use of condoms. Meta-analysis
showed that interventions did not significantly affect
adolescents’ condom use during intercourse (OR 1.04;
95% CI 0.87-1.24) [65-76], however, these results must
be interpreted cautiously since the outcome was not
uniformly defined (Figure 7).
Strong empirical evidence illustrates that other STIs,
especially ulcerative diseases and HSV-2, promote HIV
transmission with risk increased by 2-5 times that in the
general population [95,96]. STIs can therefore interfere
with the effectiveness of other interventions to prevent
HIV [97]. Management of STIs, including screening,
counseling and treatment, has been shown to reduce the
risk of HIV. This review found a non-significant slightly
decreased risk (RR 0.83; 95% CI 0.63-1.09) since it only
included arms of factorial trials in which STI manage-
ment was the only difference from the other trial arms
(Figure 8) [25,27,32,35,64].
Figure 4 Male circumcision and the risk of HIV infection: evidence from controlled trials Citations to the included studies: Auvert 2005
[47], Bailey 2007 [48], Gray 2007 [49], Wawer 2009 [50], Weiss 2000 [51]
Figure 5 Microbicides and the risk of HIV infection: evidence from controlled trials Citations to the included studies: Karim 2009 [52],
Karim 2010 [53], McCormack 2010 [54], Skoler-karpoff 2008 [55], Peterson 2007 [46]
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Behavioral interventions to reduce the risk of HIV are
heterogeneous and target different populations [87,89],
but broadly may incorporate HIV/AIDS education, con-
dom promotion and skills, peer educators, skills to
negotiate safe sexual behavior, address sociocultural bar-
riers and personal risk reduction, counseling and testing.
Overall, these interventions showed a beneficial impact
through reduction of risky sexual behaviours, and on
decreased STI incidence [86]. It appeared that interven-
tions are more effective for HIV-positive individuals
[84,85,98] and serodiscordant couples as well as high-risk
ethnic populations [77-79,81,82,90]; and if they are multi-
component, based on cognitive-behavioral theory and
provide participants with the skills to ensure safe sexual
practices. It remains unclear whether interventions have
more effect if targeted specifically by gender. Amongst
intravenous drug users, interventions (except counseling)
to prevent HIV infection do result in reduced injection
and sexual risk behavior [80,88,91,92,94]. Risk reduction
in this high-risk population through harm reduction,
substitution treatment, and peer education is important
to prevent transmission to the rest of the population.
Vaccine usage pre-conceptionally
Although vaccination has been a highly successful public
health campaign, gaps remain in coverage. Immunization
during the preconception period can prevent many dis-
eases which may have serious consequences or even prove
fatal to the mother or newborn. For example, rubella
exposure during early pregnancy can result in pregnancy
loss, stillbirths or congenital rubella syndrome. Further,
live-virus vaccines are recommended in the preconception
period because they cannot be safely administered during
pregnancy; others have maternal benefits because they
avoid treatment that might have adverse consequences for
the pregnancy.
The review intended to look at the feasibility of vacci-
nation of women while they are contemplating a preg-
nancy, focusing on how this may further decrease the
morbidity and mortality associated with gestational infec-
tions and how such vaccination could be successfully
implemented.
Four intervention trials were found that assessed the
effectiveness of tetanus toxoid vaccination in women of
child-bearing age [99-115]. Analysis showed that vaccina-
tion against tetanus averted a significant number of neona-
tal deaths (including those specifically due to tetanus)
when compared to placebo in women receiving more than
1 dose of the vaccine (OR 0.28; 95% CI: 0.15-0.52); (OR
0.02; 95% CI: 0.00-0.28) (Figure 9) respectively [101]. This
was also true for tetanus-diphtheria toxoid (OR 0.52; 95%
CI: 0.29-0.91) [99]. These findings were confirmed by
observational data from mass immunization programs of
several countries [100,102,116] and a review [117]. How-
ever, no trials were located that compared preconception
vaccination with immunization done during pregnancy.
The evidence for preconception vaccination against
rubella was from separate interventional studies for
Figure 6 Barrier methods (especially condom use) and the risk of HIV: evidence from controlled trials Citations to the included studies:
Ahmed 2001 [56], Davis 1999 [57], Pinkerton 1997 [58], Weller 2002 [59], Padian 2007 [60].
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screening and vaccination, and from observational data of
national vaccination campaigns. Antibody screening is
not advised before vaccination since it has a high rate of
false negatives [104,107]. Premarital screening increases
the rates of vaccination only when providers advise vacci-
nation and offer it directly after counseling, or other
motivation is provided with screening, such as a letter or
brochure [106,110,111,113]. National vaccination cam-
paigns for girls and women are cost-effective or cost-sav-
ing, and even if vaccination occurs within a few months
before preconception, the risk of the fetus developing
congenital rubella syndrome from vaccination is at most
1.7% [103,105,108,109,112,114,115]. In only one trial was
the rate of neonatal death higher in the vaccination arm
Figure 7 Interventions to prevent HIV in adolescents: evidence from controlled trials Citations to the included studies: Goldfarb 1999[65],
Jemmott 1998[66], Trenholm 2007[67], Boekeloo 1999[68], Dilorio 2006[69], Kirby 1997[70], Philliber 2001[71], Sikkema 2005[72], Stanton 1996[73],
Stanton 2006[74], weeks 1997[75], Wu 2003[76].
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(1.2% versus 0% in controls). Finally, if women are found
to be non-immune after delivery, it is advisable that they
be vaccinated in the postpartum period to provide pro-
tection for the subsequent pregnancy.
The advantage of administering the HPV vaccine to
prevent cervical cancer means that girls must be vacci-
nated before the onset of sexual activity [118]. HPV vac-
cination provides further advantage, however, to young
women and their newborns by reducing the possibility of
preterm birth due to cervical incompetence and the rate
of laryngeal papillomatosis in the newborn [119]. In
phase 3 clinical trial and post-licensure surveillance, the
only significant difference in neonatal outcomes was
found for miscarriage when Cervarix was administered
within 3 months preconception [120,121].
Periodontal disease and dental caries
Preterm birth and LBW is a leading cause of neonatal and
infant mortality and morbidity. In attempting to reduce
this burden of disease, it was first necessary to understand
the mechanism by which preterm birth occurs; Golden-
berg et al. [122] was the first to suggest that infection of
the maternal-fetal membranes was responsible for early
spontaneous preterm birth. While it was easily conceivable
that direct infection, for example from bacterial vaginosis,
could lead to preterm labor, around the same time Offen-
bacher et al. [123] demonstrated that periodontitis was
also a risk factor for preterm birth.
Given the surprisingly high odds (OR 7.5) that maternal
periodontal disease could result in preterm LBW babies,
researchers sought to confirm this effect and examine
Figure 8 Management of STIs and the risk of HIV: evidence from controlled trials Citations to the included studies: Celum 2010[64],
Grosskurth 1995[35], Kamali 2003[25], Kamb 1998[32], Wawer 1999[27].
Figure 9 (a) Women immunized with Tetanus toxoid versus influenza vaccine and odds of neonatal deaths (b) Women immunized
with Tetanus toxoid versus influenza vaccine and odds of tetanus specific neonatal deaths Citation to included study: Newell 1966[101]
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whether improving maternal oral health would improve
pregnancy outcomes. Systematic reviews incorporating epi-
demiologic and interventional evidence have not consis-
tently supported the association [124-127]. Meta-analyses
of risk aversion, however, seem to acknowledge the rela-
tionship (OR for association with preterm LBW ranging
from 2.83-4.28; and OR for association with other adverse
pregnancy outcomes including miscarriage, intrauterine
growth restriction, gestational diabetes and preeclampsia
range from 1.10-20.0) with reservation [128-130]. Further,
clinical trials that assess periodontal treatment have found
differential effects on pregnancy outcomes [131]. Reviews
[132,133] seeking to explain these inconsistencies have
cited lack of uniform definitions for exposure and out-
comes; failure to control for confounders that are known
risk factors for preterm birth; the use of just a single ses-
sion of treatment; and the possibility that ameliorating this
risk might only improve outcomes in a subpopulation.
Since periodontal infection is presumably chronic, it is
reasonable to suppose that prevention and/or treatment
before pregnancy might help women maintain good oral
health during pregnancy and prevent adverse outcomes.
However, most risk-aversion studies and clinical trials
have been conducted during pregnancy.
Oittinen et al. 2005 [134] was the only study found
that exclusively focused on pre-pregnancy periodontal
infection and adverse pregnancy outcome (miscarriage
and preterm birth not disaggregated) and showed an
OR 5.5 (95% CI 1.4-21.2). Interestingly they found no
effect for dental caries (OR 1.0). A cohort study [135]
was excluded since periodontal treatment or prevention
were not explicitly stated as being provided before
pregnancy.
Cytomegalovirus
Cytomegalovirus (CMV) is the most common congenital
viral infection, and is a leading cause of congenital deaf-
ness and neurodevelopmental disability. Between 0.2
and 2.5% of all live newborns are infected [136]. Ten
percent of these will be symptomatic at birth, and of the
remaining, another 10% will also go on to develop dis-
ease sequel [137]. Managing children with the perma-
nent consequences of congenital CMV costs over
$300,000 annually per child, and more children suffer
from such outcomes each year than from any other con-
genital defect [136]. The annual seroconversion rate for
pregnant women is 2.3% [138], and the greatest risk is
incurred by newborns whose mothers acquire the pri-
mary infection during pregnancy (1% of pregnancies)
since the intrauterine transmission rate is 40% or higher
and decreases with increasing gestational age [139].
The propensity for newborns to acquire the infection
from their mothers and the devastating consequences of
congenital CMV infection has motivated researchers to
try and develop a vaccine. Such efforts have been ham-
pered, however, by confusion as to whether maternal
immunity actually provides protection for the fetus- 60%
of infants with CMV are born to mothers who were
immune before pregnancy [140]. This review, therefore,
examined the neonatal outcomes for women who were
infected pre-pregnancy, and therefore developed immu-
nity to CMV.
The studies pertaining to preconceptional immunity to
CMV and fetal infection were all observational (includ-
ing cohort) studies. In one study [141], of 46 newborns
to women with preconceptional immunity, 16 were
infected with CMV. Sixty two percent (62%) of the
mothers with infected infants versus 13% of those with
uninfected infants had acquired new antibody specifici-
ties, indicating that maternal reinfection with a different
strain of CMV could still lead to congenital infection.
Fowler et al. [142] showed that preconceptional immu-
nity (seropositive at a previous birth) resulted in a signifi-
cantly lowered risk (RR 0.31) of infection in the newborn.
Shaamash et al. [143] also showed that preconceptional
(not clearly defined, since blood sample taken during
antenatal visit) immunity ameliorates disease, even if it
does not block transmission with infants of 132 seroposi-
tive women all being asymptomatic- this includes 2 infant-
mother pairs with recent infection.
Further research tried to delineate whether the timing of
the primary infection in relation to conception was a risk
factor: Daiminger et al. 2005 [144] showed that women
with primary infection 2 months to 2 weeks pre-pregnancy
did not have infected infants, whereas women with primary
infection in 1 week before to 1 month after conception had
similar rates of transmission as those women acquiring
CMV during pregnancy. These results are somewhat mis-
leading, however, since exposure for 10 women could not
be definitively categorized as preconceptional or pericon-
ceptional. The distinction between primary preconceptional
(3 months before) and periconceptional (1 month after)
exposure was also made by Revello & Gerna 2002 [145]
with a higher rate of congenital infection in the periconcep-
tional exposure group. Fowler et al. 2004 [146] also demon-
strated that among mothers who seroconverted between
pregnancies, the risk was greatest for those with birth inter-
vals <24 months. Moreover, the risk may also depend on
endemicity, indicated by maternal sero-prevalence rates
[147].
More recently, Revello et al. 2006 [148] showed that of
14 women who had primary CMV infection 2 weeks to 4.5
months before pregnancy, only 1 had an infected newborn
(another 1 terminated her pregnancy). Hadar et al. 2010
[149] confirmed these results (periconception defined as 1
month prior to 3 weeks after conception) in a larger group
of women with primary infection. Zalel et al. 2008 [150]
however, studied 6 women with preconceptional immunity,
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all of whom had severely infected fetuses, proving that
recurrent infection can be as hazardous as primary infec-
tion in pregnancy.
Discussion
It is well known that the best time to identify and address
risk factors for poor reproductive health outcomes for
mothers and babies is not after but before conception
through preconception care [98]. Infections are one of
those risks, because certain infectious diseases carry a
real threat to mothers and the foetus in utero. STI are
serious global reproductive health problem, the burden is
high among women from poor socio-economic status.
This review identified that mass treatment of STIs with
antibiotics leads to a 22% reduction in its prevalence, and
behavioral/counseling interventions, on the other hand,
led to a 35% decrease in STI incidence. Interventions tar-
geting STIs led to a significant 26% increase in condom
use. This finding is in line with the systematic review
[151] on effectiveness of condoms in reducing STIs like
chlamydia and gonorrhea. A Systematic review by Shep-
herd et al. [152] on the effectiveness of behavioral inter-
ventions for prevention of STIs in adolescents and young
adults also showed that behavioral programs bring about
increase in knowledge and self-efficacy and changes in
behavioral outcomes to a lesser degree. The review did
not study the effects on MNCH outcomes, henceforth, it
concluded that such school-based skills and information
interventions play a significant role in improving overall
knowledge about the subject, foster favorable attitudes
and ‘behavioral intentions’.
Studies that assessed the impact of PrEP found non-sig-
nificant lower incidence of HIV/AIDS, similarly, ART also
found lower incidence of HIV/AIDS. However, concerns
with PrEP include adherence, the risk of developing resis-
tant viral strains, safety, cost and behavioral risk compen-
sation. Condom use is scientifically proven to radically
diminish the risk of HIV transmission, and condoms have
the additional advantage of protecting against other STIs
and unintended pregnancy [153]. Since other contracep-
tive methods, especially those that are female-dependent,
are not effective, there is a real need for methods to
increase condom use among serodiscordant partners and
other individuals that are high-risk for HIV transmission
[154]. Research should now focus on developing effective
interventions, assessed through rigorous methods, to pro-
mote the use of condoms during all sexual exposures. It
was also hoped that microbicides might provide a way for
women to control their risk for HIV infection, however,
microbicides do not provide protection from HIV and
might even increase harm through increased risk of genital
ulceration and injury. Voluntary counseling and testing, on
the other hand, has also not shown to reduce the risk of
transmission through unprotected intercourse; however it
is still advocated for individuals to determine their serosta-
tus, in order to better protect themselves and others
[61-63]. Behavioral interventions showed a beneficial
impact through reduction of risky sexual behaviors, and
on decreased STI incidence. However, the reduction in
HIV incidence was less convincing. The lack of consistent
effect across studies might be due to differing sites and
populations [83], and the use of different control groups. .
While there is a definite need for more HIV prevention
interventions that are specifically effective in women,
reducing HIV incidence in the general population will
decrease the probability that women are exposed to HIV.
Ongoing trials may provide evidence for pre-exposure
prophylaxis and prove that treatment is effective as pre-
vention. Men who are circumcised halve their chances of
becoming infected, and of further transmitting it to their
female partners STI, especially ulcerative types such as
HSV-2, significantly increase the risk of becoming HIV-
infected. However, pooling results of participants in ran-
domized trials who only differed from the controls in
terms of STI management did not yield significant evi-
dence of effect. Screening and management of STIs is
still promoted, because individuals with STIs have both
increased biologic and behavioral risk. The components
of behavioral interventions that increase likelihood of
success in preventing HIV have been documented; how-
ever non-uniform reporting of outcomes limits compari-
son of effect for populations and high-risk groups. Even
in endemic regions, such as sub-Saharan Africa, there
have been few interventions carried out in youth, who
are at high-risk of HIV infection [155]. Proof of efficacy
must now be translated into effectiveness, through repli-
cation of successful interventions in various contextual
settings and target populations, and reporting of standar-
dized and biologic outcomes (especially HIV incidence).
A number of best practice interventions have been iden-
tified to prevent HIV infection in high-risk individuals
[93]. Adolescents are a special group with unique social
influences, and are at extremely high risk. Many reviews
have been conducted in this area, but data synthesis has
tended to be qualitative, or has focused on a single type of
intervention. It is crucial to note here that interventions
which aim to prevent STIs including HIV, and teenage
and unintended pregnancies, overlap to a large extent.
Further, there is a lack of uniformity in the outcomes that
trials report- for instance, some report STI incidence and
others prevalence or repeat infections; and some discuss
unprotected intercourse while others assess condom use
at last intercourse. On the other hand, such outcomes may
have been assessed in more than one way to ensure
response accuracy. Surprisingly few trials report public
campaigns as an intervention or HIV incidence as an out-
come, despite evidence to show the high rates of infection
and risky sexual behavior among teens. Preconception
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counseling should be offered to women of reproductive age
as soon as they test HIV-positive, and conversely women of
reproductive age should be screened with their partners
before pregnancy. While many interventions have been
tested they mostly look at endpoints such as safer sexual
behavior. These would eventually have an indirect effect on
possibly reducing adverse pregnancy outcomes, however
the need of the hour are epidemiologic studies that better
address the issue at hand - reducing STIs in women in the
preconception period to have immediate and large impacts.
Tetanus vaccination (with Tdap) of women of child-
bearing age has been found to be effective in reducing
neonatal deaths from the disease (48%), especially when
immunization is complete. Immunization during preg-
nancy with tetanus toxoid is the general practice in cur-
rent obstetrics guidelines. All women of reproductive age
should receive immunization against rubella if they have
no evidence of immunity. Rubella vaccination before
pregnancy is safe, even in the periconception period, and
protects newborns from congenital rubella syndrome.
Clinical trials of HPV vaccination in the preconception
period have been shown to be safe, and as national cam-
paigns immunize more women, further evidence of bene-
fit on preterm birth might be found. The effects of pre-
pregnancy immunization on MNCH outcomes need to
be compared with immunization during pregnancy. Also
the duration for which these may be efficacious should
be investigated, so that if necessary, women receive boos-
ter vaccinations before subsequent pregnancies.
While it is tempting to extrapolate the evidence for
periodontal treatment during pregnancy to the precon-
ception period, high level evidence is still lacking to
prove that prevention or treatment of periodontal dis-
ease before or during pregnancy consistently prevents
adverse outcomes. Further large-scale randomized con-
trolled trials are necessary to establish that such therapy
is warranted. Further, it must be noted that like many
other interventions, such therapy might need to be a
process that is instituted before, but continues through-
out pregnancy, in order to achieve the maximum bene-
fit. Currently, preconception screening and treatment of
periodontal disease can only be recommended to
improve women’s oral health.
Although the evidence is still far from concrete, it
appears that preconceptional immunity does provide some
protection to the fetus from CMV infection. However,
recurrent or periconceptional maternal infection are as
risky as infection during pregnancy. For the same reason,
and due to cost constraints, maternal screening is also not
advised unless the woman is symptomatic or there is evi-
dence of fetal infection. While observational studies with
larger sample sizes may provide clarity as to whether a
vaccine could be effective, women of reproductive age
should be counseled on how to reduce their exposure to
CMV around pregnancy [136,139]. Young children are the
main source of CMV infection, and therefore women
planning to conceive should be counseled to avoid contact
with children’s saliva or urine, and wash hands thoroughly
if such contact occurs. Further, women of reproductive
age diagnosed with primary CMV infection should be
counseled to delay pregnancy, although the minimum
interval is not yet clear [137]. Some evidence also suggests
that CMV hyper immune globulin could be administered
for both therapeutic and preventive purposes [156].
Conclusion
It is very important to address these infectious diseases in
preconception period. Risk assessment, screening, and
treatment for specific infections should be a component of
preconception care because there is convincing evidence
that treatment of these infections before pregnancy pre-
vents neonatal infections; consequences to the developing
fetus (syphilis); or transmission of an infectious agent with
potential for chronic infection of the offspring (HIV).
Given the association of periodontal disease with preterm
birth in observational studies, trials to evaluate specifically
the effect of preconception treatment interventions for
these conditions are warranted.
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